Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + BR for Waldenström Macroglobulinemia
NCT07169565Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bendamustine in Waldenström macroglobulinemia (WM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities, Maximum Tolerated Dose at 6 months and 3 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
bendamustine
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07169565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169565.